BMI View: Canada's epidemiological profile will continue to be attractive to manufacturers of medicines
for non-communicable diseases. Despite the relatively rapid uptake of innovative pharmaceuticals, the
burden of chronic conditions will increase over the next 15 years. Like ..."
BMI View: The Canadian pharmaceutical and healthcare market will become increasingly attractive to
pharmaceutical companies over the next few years as economic growth in the country gradually
accelerates. The hospitable business environment, improving healthcare cover ..."
BMI View: On the back of more promising a macroeconomic outlook in 2014, we believe the Canadian
pharmaceutical and healthcare market will be more attractive to pharmaceutical companies. Although
drugmakers will continue to face generic competition and drug pricing pr ..."
BMI View: The Canadian government is leveraging direct incentives to attract multinational
pharmaceutical companies to invest in research and development in the country. In Canada's single-payer
healthcare system, patented drug sales will continue to face cost-contain ..."
BMI View: Multinational pharmaceutical companies have felt the pressure in Canada's drug market due to
the government's cost-containment policy and the significant number of blockbuster drug patent expiries;
however, there are still many opportunities for multinational drugmake ..."
BMI View: The Canadian government's focus on further cost-containment policies to healthcare overlooks
the sector's function as a generator of wealth. Canada's healthcare sector, which receives 70% of its
funding from the government, has absorbed labour forces during the econom ..."
Innovative drugmakers have experienced increasing government cost containment pressure and
generic competition in Canada. Local authority has also switched to more direct incentive to encourage
R&D investment from pharmaceutical industry. We expect the country's relatively ..."
The relatively high consumption of patented drugs in Canada in comparison with other developed countries remains a positive sign for multinational pharmaceutical companies to maintain their current sales level s by 2017. Although innovative drugmakers have also experienced gover ..."
BMI View: The relatively high consumption of patented drugs in Canada in comparison with other
developed countries remains a positive sign for multinational pharmaceutical companies to maintain
their current sales levels by 2017. Although innovative drugmakers have also experie ..."